



## **Theratechnologies enters into a bought deal agreement for \$20,475,000**

**Not for distribution to U.S. news wire services or dissemination in the united states.**

**Montreal, March 2, 2006** – Theratechnologies Inc. (TSX: TH) today announced that it has entered into an agreement with BMO Nesbitt Burns Inc, under which BMO Nesbitt Burns has agreed to buy 10,500,000 common shares from Theratechnologies and sell them to the public at a price of \$1.95 per share, representing an aggregate issue amount of \$20,475,000. The Company has also granted BMO Nesbitt Burns an option to purchase an additional 1,575,000 common shares. Closing is expected on or about March 22, 2006.

The transaction is subject to the receipt of all necessary regulatory and stock exchange approvals.

The proceeds of the transaction will be used for working capital and corporate purposes.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

### **About Theratechnologies**

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets where it can retain full or partial commercial rights for its products. Its most advanced program is TH9507, now in Phase 3 clinical trials for a serious metabolic complication known as HIV-associated lipodystrophy. The Company also has other promising projects at earlier stages of development.

### **Forward-looking statements**

*This press release contains forward-looking statements regarding the successful completion and timing of the announced financing. Such statements inherently involve numerous risks and uncertainties. Actual future results may differ materially from the anticipated results. Investors are cautioned against placing undue importance on forward-looking information contained herein and should consult pages 16 and 17 of the Company's 2005 Annual Report, which contains a more exhaustive analysis of risks and uncertainties connected to the businesses of the Company.*

###

### **Contact:**

Luc Tanguay  
Senior Vice President & chief Financial officer  
Phone: (514) 336-4804, ext. 204  
Email: ltanguay@theratech.com

Tobie Trudel  
Investor Relations  
Phone: (514) 336-4804, ext. 229  
Email: ttrudel@theratech.com